UT Health Science Center San Antonio doctor plays key role in FDA expediting hep C drugs

(University of Texas Health Science Center at San Antonio) The US Food and Drug Administration has granted amended Breakthrough Therapy Designation for a promising drug combination to treat the sickest hepatitis C patients -- those with advanced cirrhosis or who have had a liver transplant but the virus returned. The designation expedites drug development based on early results of the ALLY-1 clinical trial presented by Fred Poordad, M.D., from The University of Texas Health Science Center at San...